Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

2.2K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.2K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

6.8K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
6.8K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.9K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.9K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

9.5K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
9.5K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

3.4K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.4K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

7.2K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®).

Future oncology (London, England)·2026
Same author

Foraging benefits promote fitness in migratory mule deer.

Current biology : CB·2026
Same author

Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations.

American journal of hematology·2025
Same author

Pharmacokinetic profile of novel reduced-dose Danziten<sup>™</sup> (nilotinib tablets) versus Tasigna<sup>®</sup> (nilotinib capsules): in vivo bioequivalence and population pharmacokinetic analysis.

Cancer chemotherapy and pharmacology·2025
Same author

Recognition, prevention, and management of adverse events associated with asparaginase/ pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel.

Haematologica·2025
Same author

Therapeutic outcomes of patients with acute erythroid leukemia treated with hypomethylating agents.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2025

Related Experiment Video

Updated: Apr 23, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

809

Acute lymphoblastic leukemia in adolescents and young adults.

Patrick W Burke1, Dan Douer

  • 1Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, N.Y., USA.

Acta Haematologica
|September 18, 2014
PubMed
Summary

Adolescents and young adults with acute lymphoblastic leukemia (ALL) have poorer outcomes than children. Pediatric-inspired regimens show promise for improving cure rates in this age group.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

32.1K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K

Related Experiment Videos

Last Updated: Apr 23, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

809
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

32.1K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K

Area of Science:

  • Oncology
  • Pediatric Hematology/Oncology
  • Cancer Research

Background:

  • Acute lymphoblastic leukemia (ALL) cure rates significantly decrease in adolescents and young adults (AYAs) compared to children.
  • AYAs present unique biological characteristics and are often treated with differing approaches by pediatric vs. adult oncologists.
  • Current treatment disparities contribute to inferior outcomes for AYAs, particularly when treated with adult regimens.

Purpose of the Study:

  • To investigate the efficacy of pediatric or 'pediatrics-inspired' regimens in AYAs with ALL, including those over 21 years.
  • To identify novel mutations in AYA ALL for risk stratification and targeted therapy development.
  • To bridge the cure rate gap between pediatric and adult ALL patients.

Main Methods:

  • Application of contemporary pediatric protocols and 'pediatrics-inspired' regimens to AYA ALL patients.
  • Intensification of nonmyelosuppressive drugs like vincristine, steroids, and asparaginase.
  • Exploration of new mutations specific to AYA ALL.

Main Results:

  • Preliminary results indicate very promising outcomes with pediatric-inspired regimens in AYAs.
  • AYAs aged 15-21 treated with contemporary pediatric protocols show similar outcomes to younger children.
  • Adult regimens result in inferior outcomes for AYAs compared to pediatric protocols.

Conclusions:

  • Pediatric-inspired chemotherapy principles, intensified with specific drugs, offer a promising strategy for improving AYA ALL outcomes.
  • Identifying novel mutations in AYA ALL is crucial for personalized risk stratification and novel therapeutic targets.
  • Fine-tuning treatment approaches for AYAs is essential to reduce the disparity in cure rates compared to children and older adults.